AIM
AIM
AMEX · Biotechnology

Aim Immunotech Inc

$0.28
+0.01 (+5.02%)
As of Aug 8, 2:36 AM ET ·
Financial Highlights (FY 2026)
Revenue
1.53M
Net Income
-242,271,633
Gross Margin
-45.4%
Profit Margin
-15,861.4%
Rev Growth
-14.5%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin -45.4% -45.4% 50.8% 50.8%
Operating Margin -13,254.5% -11,929.1% -19.6% -21.6%
Profit Margin -15,861.4% -15,068.3% -22.2% -17.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 1.53M 1.79M 1.31M 1.61M
Gross Profit -694,635 -812,818 667.2K 816.8K
Operating Income -202,575,914 -213,337,611 -257,805 -347,025
Net Income -242,271,633 -255,142,136 -292,011 -275,194
Gross Margin -45.4% -45.4% 50.8% 50.8%
Operating Margin -13,254.5% -11,929.1% -19.6% -21.6%
Profit Margin -15,861.4% -15,068.3% -22.2% -17.1%
Rev Growth -14.5% -14.5% +20.5% -9.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 1.16M 1.06M
Total Equity 1.39M 1.56M
D/E Ratio 0.83 0.68
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -201,812,489 -224,341,053 -341,169 -390,753
Free Cash Flow -173,511 -203,411